Candriam SCA’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.5M | Buy |
120,238
+16,102
| +15% | +$3.16M | 0.11% | 167 |
|
|
2026
Q1 | $20.4M | Buy |
104,136
+2,409
| +2% | +$468K | 0.11% | 194 |
|
|
2025
Q4 | $17.7M | Buy |
101,727
+29,908
| +42% | +$5.45M | 0.09% | 203 |
|
|
2025
Q3 | $13.7M | Sell |
71,819
-193,952
| -73% | -$34.4M | 0.07% | 226 |
|
|
2025
Q2 | $47.7M | Sell |
265,771
-12,885
| -5% | -$2.24M | 0.28% | 86 |
|
|
2025
Q1 | $47.1M | Buy |
278,656
+110,946
| +66% | +$18.2M | 0.3% | 84 |
|
|
2024
Q4 | $25.3M | Buy |
167,710
+21,881
| +15% | +$3.4M | 0.15% | 144 |
|
|
2024
Q3 | $22.6M | Buy |
145,829
+80,966
| +125% | +$12.1M | 0.13% | 161 |
|
|
2024
Q2 | $13.4M | Buy |
64,863
+5,375
| +9% | +$736K | 0.08% | 219 |
|
|
2024
Q1 | $7.92M | Sell |
59,488
-43,359
| -42% | -$5.63M | 0.05% | 282 |
|
|
2023
Q4 | $14.2M | Sell |
102,847
-16,875
| -14% | -$2.22M | 0.1% | 213 |
|
|
2023
Q3 | $14.6M | Buy |
119,722
+17,919
| +18% | +$2.39M | 0.1% | 184 |
|
|
2023
Q2 | $14.3M | Sell |
101,803
-34,666
| -25% | -$4.78M | 0.1% | 202 |
|
|
2023
Q1 | $17.8M | Buy |
136,469
+41,398
| +44% | +$5.92M | 0.12% | 182 |
|
|
2022
Q4 | $14.9M | Buy |
95,071
+5,489
| +6% | +$789K | 0.1% | 204 |
|
|
2022
Q3 | $11M | Buy |
89,582
+28,936
| +48% | +$3.81M | 0.08% | 245 |
|
|
2022
Q2 | $8.06M | Buy |
60,646
+19,970
| +49% | +$2.72M | 0.07% | 259 |
|
|
2022
Q1 | $5.57M | Buy |
40,676
+1,629
| +4% | +$227K | 0.04% | 332 |
|
|
2021
Q4 | $6.76M | Sell |
39,047
-29,502
| -43% | -$4.49M | 0.04% | 304 |
|
|
2021
Q3 | $9.96M | Sell |
68,549
-1,946
| -3% | -$285K | 0.07% | 272 |
|
|
2021
Q2 | $9.3M | Buy |
70,495
+14,485
| +26% | +$1.9M | 0.06% | 295 |
|
|
2021
Q1 | $6.41M | Hold |
56,010
| – | – | 0.05% | 335 |
|
|
2020
Q4 | $6.67M | Buy |
56,010
+17,185
| +44% | +$2.09M | 0.05% | 344 |
|
|
2020
Q3 | $4.45M | Sell |
38,825
-2,008
| -5% | -$237K | 0.04% | 370 |
|
|
2020
Q2 | $4.65M | Buy |
40,833
+6,553
| +19% | +$695K | 0.05% | 347 |
|
|
2020
Q1 | $3.58M | Hold |
34,280
| – | – | 0.04% | 424 |
|
|
2019
Q4 | $3.66M | Buy |
34,280
+6,863
| +25% | +$716K | 0.04% | 438 |
|
|
2019
Q3 | $2.93M | Buy |
27,417
+3,132
| +13% | +$322K | 0.04% | 422 |
|
|
2019
Q2 | $2.46M | Sell |
24,285
-7,693
| -24% | -$739K | 0.03% | 474 |
|
|
2019
Q1 | $3.86M | Buy |
31,978
+9,705
| +44% | +$841K | 0.05% | 370 |
|
|
2018
Q4 | $1.85M | Buy |
22,273
+7,584
| +52% | +$711K | 0.03% | 478 |
|
|
2018
Q3 | $1.58M | Sell |
14,689
-140,052
| -91% | -$15.4M | 0.02% | 548 |
|
|
2018
Q2 | $17M | Sell |
154,741
-24,450
| -14% | -$2.55M | 0.27% | 88 |
|
|
2018
Q1 | $18M | Buy |
179,191
+22,701
| +15% | +$2.32M | 0.31% | 86 |
|
|
2017
Q4 | $15.4M | Buy |
156,490
+17,363
| +12% | +$1.65M | 0.27% | 99 |
|
|
2017
Q3 | $13M | Sell |
139,127
-22,051
| -14% | -$2.34M | 0.23% | 116 |
|
|
2017
Q2 | $17.9M | Sell |
161,178
-60,423
| -27% | -$6.39M | 0.34% | 69 |
|
|
2017
Q1 | $21.8M | Buy |
221,601
+153,816
| +227% | +$14.7M | 0.42% | 46 |
|
|
2016
Q4 | $6.23M | Sell |
67,785
-212,978
| -76% | -$18.4M | 0.14% | 178 |
|
|
2016
Q3 | $23.8M | Buy |
280,763
+63,277
| +29% | +$5.31M | 0.57% | 41 |
|
|
2016
Q2 | $17.7M | Buy |
217,486
+69,734
| +47% | +$5.31M | 0.46% | 56 |
|
|
2016
Q1 | $10.5M | Buy |
147,752
+143,323
| +3,236% | +$9.61M | 0.26% | 94 |
|
|
2015
Q4 | $315K | Sell |
4,429
-25,879
| -85% | -$1.74M | 0.01% | 505 |
|
|
2015
Q3 | $1.86M | Sell |
30,308
-70,005
| -70% | -$4.89M | 0.05% | 354 |
|
|
2015
Q2 | $7.28M | Buy |
100,313
+8,856
| +10% | +$654K | 0.15% | 184 |
|
|
2015
Q1 | $7.03M | Buy |
91,457
+85,874
| +1,538% | +$6.15M | 0.14% | 194 |
|
|
2014
Q4 | $374K | Buy |
+5,583
| New | +$352K | 0.01% | 548 |
|
Other funds holding DGX
EIG
Candriam SCA's DGX Position: Q2 2026 in Review
Candriam SCA increased its Quest Diagnostics (DGX) stake by 15% in Q2 2026, buying an estimated $3.16M and bringing the position to 120,238 shares worth $25.5M. The position accounts for 0.11% of the portfolio, ranked #167.
Candriam SCA first reported a position in DGX in Q4 2014 and has held it in 47 quarters since. The position peaked at $47.7M in Q2 2025. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Candriam SCA held 120,238 shares of Quest Diagnostics worth $25.5M as of Q2 2026.
- Candriam SCA bought 16,102 Quest Diagnostics shares in Q2 2026, an estimated $3.16M.
- Quest Diagnostics made up 0.11% of Candriam SCA's portfolio in Q2 2026, its #167 holding.
- Candriam SCA first reported a position in Quest Diagnostics in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Quest Diagnostics position peaked at $47.7M in Q2 2025.
- 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.